• We commenced the commercialization and launched XTR005 (欧韦宁®) in hospitals across China, achieving GMP-standardized production and commercialization

• We were awarded the national “Specialized, Refined, and New ‘Little Giant’” (国家级专精特新“小巨人”企业) enterprise title
• Jiangsu Sinotau Pharmaceutical obtained the Radiopharmaceutical Business License (放射性药品经营许可证)
• We completed the Nov-2024 Capital Increase and the Dec-2024 Capital increase and raised approximately RMB600 million in aggregate

• We completed Jun-2023 Capital Increase and raised approximately RMB1,100 million.
• We received regulatory approval from NMPA for XTR005 (欧韦宁®)
• Glotope commenced radiopharmaceutical CRO/CDMO business
• We obtained clinical trial approval for XTR006

• Shanghai Sinotau was established.
• We obtained clinical trial approval for XTR008.

• We obtained clinical trial approvals for XTR003 and XTR004.

• We obtained clinical trial approval of XTR005 (欧韦宁®), the first
  radiopharmaceutical clinical trial approval we obtained .
• We completed the Division and focusing on the radiopharmaceutical market.

• We voluntarily delisted from the NEEQ.

• We listed on the NEEQ.

• Started the research and development of radiopharmaceutical.

Our Company was established